MDS Virtual Congress 2020 Archives - Page 55 of 149

Pain syndrome in Parkinson’s disease: neurophysiological and MRI morphometric features

O. Alenikova, I. Goursky, N. Alenikov (Minsk, Belarus)
Pain Syndromes in Parkinsonism Depending on the Form Disease

N. Nurmuxamedova, R. Matmurodov, E. Abduqodirov (Tashkent, Uzbekistan)
Painful Legs and Moving Toes (PLMT): A Case Series

N. Labaure, I. Amorin, A. Lescano, G. Morando (Montevideo, Uruguay)
Palliative care and Parkinson’s disease: current practice, knowledge and barriers to referral; Insights from palliative care units in Brittany, France

M. Auffret, J. Keromnes, G. Robert, V. Morel, M. Vérin (Rennes, France)
Pallidal deep brain stimulation in GNAO1 mutation dystonic storm: a description of two pediatric cases

E. Luque Buzo, O. Sierra Mateo, M.C Miranda Herrero, J.R Pérez Sáchez, C. Fernandez Carballal, B. Casa Fages, M. González Sánchez, A. Contreras Chicote, M. Vázquez López, J.M Garbizu Vidorreta, P. Castro Castro, F.J Grandas Pérez (Madrid, Spain)
Pantothenate kinase associated neurodegeneration: A familial case report of two sisters with severe dystonia

B. Tserensodnom (Ulaanbaatar, Mongolia)
Pareidolias and Cognition in Isolated REM Sleep Behavior Disorder

L. Honeycutt, J.F Gagnon, A. Pelletier, J. De Roy, J. Montplaisir, R. Postuma (Montreal, QC, Canada)
PARK2 p.Ala82Glu variant is not associated with Parkinson’s disease

L. Milanowski, B. Broadway, F. Fiesel, D. Hoffman-Zacharska, D. Koziorowski, A. Friedman, J. Slawek, O. Ross, W. Springer, Z. Wszolek (Jacksonville, FL, USA)
Parkinson disease phenotype classification predicts the outcome of deep brain stimulation

C.A Artusi, A. Romagnolo, G. Imbalzano, E. Montanaro, M. Zibetti, M. Rizzone, L. Lopiano (Torino, Italy)
Parkinson Progression Marker Initiative 2.0 – New Science/New Cohorts

K. Marek, A. Siderowf, T. Simuni, C. Tanner (New Haven, CT, USA)
Parkinson’s Disease – The Unseen Side of Neurologic Chronic Illnesses – The Non-Motor World of Our Existence

J. Baumann (Louisville, KY, USA)
Parkinson’s disease and chronic inflammatory demyelinating polyneuropathy with celiac disease: Improvement in neuropathy but not Parkinson’s symptoms after intravenous immunoglobulin and gluten free diet

M. Pullman, T. Brannagan, R. Saunders-Pullman (New York, NY, USA)
Parkinson’s Disease and the Law: Motor and Non-Motor Determinants in Medical Courts Cases

P. Amami, D. Ziemele, A. Albanese (Rozzano, Italy)
Parkinson’s Disease Clinical Subtypes: Symptom Progression, Dementia, and Mortality

P. Myers, J. Jackson, A. Clover, C. Lessov-Schlaggar, E. Foster, J. Perlmutter, M. Campbell (St. Louis, MO, USA)
Parkinson’s Disease Exhibits Longitudinal Increases in beta-Amyloid in the Striatum and Cingulate Gyrus

J. O'Donnell, Y. Zhou, M. Campbell, B. Maiti, J. Perlmutter (Saint Louis, MO, USA)
Parkinson’s disease patients at Hoehn and Yahr stage 1 show deficits in reactive but not proactive inhibitory control

V. Di Caprio, N. Modugno, C. Mancini, E. Olivola, G. Mirabella (Pozzilli, Italy)
Parkinson’s disease and osteocalcin pilot study: Is there a protective role of bone in neurodegeneration?

A.S Nordvig, R.N Alcalay, J.M Berger, K. Marder, G. Karsenty, A. Wang (New York, NY, USA)
Parkinson’s disease determinants, prediction and gene-environment interactions in the UK Biobank

D. Belete, B. Jacobs, J. Bestwick, C. Blauwendraat, S. Bandres-Ciga, K. Heilbron, R. Dobson, M. Nalls, A. Singleton, J. Hardy, G. Giovannoni, A. Lees, A. Schrag, A. Noyce (London, United Kingdom)
Parkinson’s Disease in Israel – Initial Symptoms and Comorbidities from 20 years of Follow Up in a Population-based Cohort

Y. Barer, N. Gavrielov, P. Coloma, M. Martinec, I. Korolev, I. Goldshtein (Tel Aviv, Israel)
Parkinson’s Disease in the Middle East, North Africa and South Asia: A Scoping Review

H. Khalil, J. Siddiqui, L. Chahine, Z. Aldaajani, M. Abu Al-Melh, F. Abdullah, H. Amer, M. Ben Djebara, M. Salari, S. Khan, W. Regragui, M. Abu Snineh, S. Mittat, J. Bajwa (Irbid, Jordan)
Parkinson’s Disease patients with diplopia exhibit visuospatial and visuoperceptive impairment

W. Naumann, J. Gogarten, S. Schoenfeld, F. Klostermann, F. Marzinzik, K. Schindlbeck (Berlin, Germany)
Parkinson’s disease polygenic risk prediction and haplotype analysis in a South American cohort

D. Loesch, A. Horimoto, E. Sarihan, M. Cornejo-Olivas, L. Torres, M. Inca-Martinez, P. Mazzetti, C. Cosentino, E. Dieguez, V. Raggio, A. Lescano, V. Tumas, V. Borges, H. Ferraz, C. Rieder, A. Schumacher-Schuh, B. Lopes Santos-Lobato, C. Velez-Pardo, M. Jimenez-Del-Rio, F. Lopera, P. Chana-Cuevas, W. Fernandez, G. Arboleda, H. Arboleda, C. Arboleda-Bustos, D. Yearout, C. Zabetian, T. Thornton, T. O'Connor, I. Mata (Baltimore, MD, USA)
Parkinson’s disease polygenic risk score and brain structure in neurologically healthy individuals

N. Abbasi, L. Krohn, U. Vainik, Z. Gan-Or, A. Dagher (Montreal, QC, Canada)
Parkinson’s disease-related pattern using resting-state functional MRI: Validation and refinement

A. Rommal, A. Vo, K. Schindlbeck, S. Peng, A. Greuel, M. Ruppert, C. Eggers, D. Eidelberg (Manhasset, NY, USA)
Parkinson’s Foundation Physical Therapy Faculty Program Evaluation

M. Rafferty, L. Hoffman, L. King, T. Ellis, F. Horak (Chicago, IL, USA)
Parkinsonism secondary to mercury poisoning in a Colombian population

J. Vargas (Bogotá, Colombia)
Parkinsonism, delayed chorea and dystonia caused by extrapontine myelinolysis

N.A Gandarilla Martínez, H.R Martínez Hernández (Mexico City, Mexico)
Paroxysmal Kinesigenic Dyskinesia: Case series from Çukurova University, Turkey

M. Demirkiran, M. Balal, A. Bisgin, S. Bozdogan (Adana, Turkey)
PASADENA: A Phase 2 study to evaluate the safety and efficacy of prasinezumab in early Parkinson’s disease; Part 1 Week-52 results

G. Pagano, K. Taylor, J. Cabrera, M. Marchesi, W. Zago, R. Tripuraneni, A. Boulay, A. Vogt, F. Boess, T. Nikolcheva, H. Svoboda, M. Britschgi, F. Lipsmeier, M. Lindemann, S. Dziadek, J. Azulay, B. Mollenhauer, L. Manzanares, D. Russell, J. Boyd, A. Nicholas, M. Luquin, R. Hauser, T. Simuni, T. Gasser, W. Poewe, G. Kinney, R. Doody, P. Fontoura, D. Umbricht, A. Bonni (Basel, Switzerland)
Passive monitored daily motor behavior significantly relates to quality of life in early Parkinson’s disease

A. Thomann, K. Taylor, F. Lipsmeier, E. Volkova-Volkmar, R. Postuma, W.Y Cheng, B. van Lier, D. Trundell, W. Zago, A. Boulay, G. Pagano, C. Gossens, M. Lindemann (Basel, Switzerland)
Passively measuring motor behavior in daily life: preliminary reliability and validity in individuals recently diagnosed with Parkinson’s disease

F. Lipsmeier, K. Taylor, A. Thomann, R. Postuma, W. Cheng, B. van Lier, E. Volkova-Volkmar, D. Trundell, W. Zago, A. Boulay, G. Pagano, C. Gossens, M. Lindemann (Basel, Switzerland)
Patient Characteristics, Treatment Patterns and Disease Burden in People with Parkinson’s Disease: Insights from the Parkinson’s Disease Real-World Impact Assessment (PRISM) Study

T. Foltynie, E. Tolosa, J. Ferreira, A. Antonini, A. Lees, G. Ebersbach, O. Rascol, J.F Rocha, D. Magalhães, P. Soares-da-Silva (London, United Kingdom)
Patient experience interviews to inform a digital assessment of Parkinson’s disease

A. Thomann, D. Nobbs, H. Staunton, D. Trundell, S. Winkelmann, T. Kilchenmann, C. Lansdall, C. Gossens, F. Lipsmeier, M. Lindemann, K. Taylor (Basel, Switzerland)
Patient experiences of cervical dystonia management with botulinum toxin A: A comparison of US versus European survey findings

C. Comella, J. Ferreira, M. Azoulai, E. Pain, S. Om (Chicago, IL, USA)
Patient Perspective of Tardive Dyskinesia: Results from a Social Media Listening Study

L. Lundt, M. Farrar, E. Franey, C. Yonan (San Diego, CA, USA)
Patient survey on personal preferences and choices regarding Advance Care Planning(ACP) in Parkinson’s Disease(PD)

M. Khwaja, A. Chatterjee (Reading, United Kingdom)
Patients’ Perceptions of Herbal Medicine for Parkinson’s disease: Thai Perspectives on Cannabis and Mucuna Pruriens

T. Boonmongkol, O. Phokaewvarangkul, R. Bhidayasiri (Bangkok, Thailand)
Patients’ perspectives on shared decision-making in Parkinson´s disease

E. Gülke, C. Wargel, A. Rahn, A. Solari, C. Buhmann, C. Gerloff, C. Heesen, M. Pötter-Nerger (Hamburg, Germany)
Patients’ perception of Deep brain stimulation in generalized dystonia

V. Vuletic (Rijeka, Croatia)
Pattern of cerebral perfusion in early de novo Parkinson’s disease with mild cognitive impairment using voxel-based analysis of 3D arterial spin-labeling imaging

L. Jin, J. Wang, Y. Zhang, C. Wang, T. He (Shanghai, China)
PD Conversations: Creation of an Online Parkinson’s Community

N. Yarab, D. Ojeda, J. McClure, A. Janicke, V. Todaro, L. Pearl, C. Whitlock, A. Diaz (Miami, FL, USA)
Perceived Stigma in Patients with Functional Movement Disorder: A Qualitative Study

L. Flaherty, C. Girgis, D. DiGasbarro, D. Mohanty, K. LaFaver (Louisville, KY, USA)
Perceptions of burden of spasticity and treatment satisfaction among post-stroke patients over the course of a botulinum neurotoxin A (BoNT-A) treatment cycle: An ethnographic study

J. Jacinto, A. Lysandropoulos, A. Fulford-Smith (Estoril, Portugal)
Performance at the Category-Exemplars language test (CATEX) in Parkinson’s disease and Huntington’s disease Italian population

R. Biundo, T. Gandolfi, M. Garon, E. Fiorenzato, G. Arcara, C. Jaquemont, P. Bisiacchi, C. Semenza, A. Antonini (Venice-Lido, Italy)
Perillyl alcohol restores mitochondrial dysfunction and abridge NLRP3 inflammasomes activation in in-vitro and in-vivo model of Parkinson’s disease

P. Panda, S. Ahmed, V. Naidu (Kamrup, India)
Peripheral neuropathy in de novo patients with Parkinson’s disease

J.S Baik, H.I Ma (Seoul, Republic of Korea)
Persistent head dyskinesias following STN DBS in Parkinson’s disease resolve using directionality

C. vander Linden, C. Bogaert-Miclaus, D. Colle (Ghent, Belgium)
Personal Kinetigraph and Deep Brain Stimulation with Parkinson’s Disease

A. Potter, G. Newsome, G. Kern, A. Parsons, D. Page, Y. Dalati, C. Sidiropoulos MD (East Lansing, MI, USA)
Perspectives on care for late stage Parkinson’s disease

K. Rosqvist, M. Kylberg, C. Löfqvist, A. Schrag, P. Odin, S. Iwarsson (Lund, Sweden)
Pesticide Exposure in PD with and without Genetic Risk Variants

E. Brown, C. Meng, S. Goldman, C. Tanner (San Francisco, CA, USA)
Pet ownership associated with lower apathy and motor severity in female participants with PD

A. Metcalfe-Roach, M. Cirstea, A. Yu, E. Golz, K. Sundvick, D. Kliger, B. Finlay, S. Appel-Cresswell (Vancouver, BC, Canada)
PF-QII Analysis of Deep Brain Stimulation versus Levodopa-carbidopa Intestinal Gel: Real-world Differences in Patient Characteristics and Quality of Life Outcomes

N. Shetty, C. Zadikoff, S. Wu, Y. Wu, T. Simuni (Chicago, IL, USA)
Pharmacokinetics and Biomarker Changes in NILO-PD, A Phase 2A Study of Nilotinib in Patients with Moderate to Advanced Parkinson’s Disease

K. Merchant, T. Simuni, B. Fiske, C. Coffey, H. Matthews, R. Wyse, P. Brundin, D. Simon, M. Schwarzschild, D. Weiner, J. Adams, L. Trusso, L. Baker, M. Kostrzebski, T. Ward, G. Rafaloff, C. Venuto (Chicago, IL, USA)
Pharmacokinetics of Levodopa in patients with Parkinson’s disease: Efforts toward a predictive model

N. Nishikawa, H. Iwaki, T. Shiraishi, Y. Mukai, Y. Takahashi, N. Hattori (Kodaira, Japan)
Phase I Study Design of a Leucine-Rich Repeat Kinase 2 (LRRK2) Antisense Oligonucleotide, for Parkinson’s Disease

J. Shirvan (Cambridge, MA, USA)
Phase I-II first-in-human clinical study of intraputamenal CDNF in Parkinson’s disease: Exploratory PET imaging endpoints of the 12-month treatment period

V. Kerstens, P. Fazio, J. Johansson, T. Granberg, S. Booms, H. Huttunen, M. Sjögren, M. Woolley, B. Murphy, P. Fielder, J. Baker, P. Skinner, M. Andreasson, G. Paul-Visse, R. Kivisaari, H. Bjartmarz, G. Lind, P. Almqvist, F. Scheperjans, H. Widner, P. Svenningsson, J. Rinne, A. Varrone (Stockholm, Sweden)
Phase I-II first-in-human clinical trial of intraputamenal CDNF in Parkinson’s disease: Exploratory fluid-based biomarker endpoints of the 12-month treatment period

H. Huttunen, S. Booms, H. Abdesselem, N. Majbour, O. El-Agnaf, I. Poggiolini, L. Parkkinen, A. Cryar, E. Sirka, J. Harris, M. Dove, M. Sjögren, M. Woolley, B. Murphy, P. Fielder, J. Baker, P. Skinner, M. Andreasson, G. Paul-Visse, R. Kivisaari, H. Bjartmarz, P. Almqvist, P. Almqvist, G. Lind, F. Scheperjans, H. Widner, P. Svenningsson (Espoo, Finland)
Phase I-II first-in-human clinical trial of intraputamenal CDNF in Parkinson’s disease: Topline results of the six-month double-blind placebo-controlled main study and the six-month active treatment extension study

S. Booms, H. Huttunen, J. Koskinen, M. Sjögren, M. Saarma, M. Woolley, B. Murphy, P. Fielder, J. Baker, P. Skinner, J. Rinne, A. Varrone, M. Andreasson, G. Paul-Visse, R. Kivisaari, H. Bjartmarz, G. Lind, P. Almqvist, F. Scheperjans, H. Widner, P. Svenningsson (Espoo, Finland)
Phenotype of Parkinson’s Disease in African Americans Using NIH Toolbox Motor Measures

M. Bailey, G. Stebbins, S. Anderson, D. Hall (Chicago, IL, USA)
Phenotypic analysis of subjects with homozygous and compound heterozygous PANK2 mutations in a single extended pedigree from the Dominican Republic (DR) PKAN cohort

F. Middleton, C. Muniz, I. Ojukwu, M. Santana Jimenez, P. Stoeter, R. Ericson, A. Espinoza, C. Bass, P. Roa, S. Baser (Santo Domingo, Dominican Republic)
Phenotypic heterogeneity in Chinese dystonia patients with KMT2B variants

X.Y Li, L. Wang, X.H Wan (Beijing, China)
Phenotyping spasticity-associated tonic spasms: implications for therapy

H. Abboud, S. Saad, M. Elkasaby, C. Kilbane (Cleveland, OH, USA)
Photophobia and Progressive Supranuclear Palsy

K. Hay, D. Mohanty, Y. Lin, H. Kang, J. Sellers-Gibson, D. Claassen (Nashville, TN, USA)
Physical Therapy and Deep Brain Stimulation in Parkinson Disease: A Pilot Randomized Controlled Trial

R. Duncan, K. Rawson, G. Earhart, L. Van Dillen, J. Perlmutter (Saint Louis, MO, USA)
Physical Therapy Role with Differential Diagonosis and Treatment with Dizziness and Multiple System Atrophy: A Case Study

J. Liu (Sacramento, CA, USA)
Physiologically-based pharmacokinetic modeling of nilotinib to determine serum, cerebrospinal fluid, and brain exposures

C. Venuto, T. Simuni, B. Fiske, C. Coffey, H. Matthews, R. Wyse, P. Brundin, D. Simon, M. Schwarzschild, D. Weiner, J. Adams, L. Trusso, M. Kostrzebski, T. Ward, G. Rafaloff, K. Merchant (Rochester, NY, USA)
Physiotherapy: Functionality and Cognition in Parkinson’s Disease

A.C Loureiro, B. Yamaguchi, V. Israel (Curitiba, Brazil)
Pill burden reduction in patients with advanced Parkinson’s disease: Comparative effectiveness of carbidopa/levodopa enteral suspension and Deep brain stimulation

M. Soileau, F. Pagan, A. Fasano, R. Rodriguez-Cruz, M. Oh, P. Kandukuri, Y. Jalundhwala, Y. Bao, P. Kukreja, M. Siddiqui (Georgetown, TX, USA)
PKAN is associated with significant peripheral metabolic alterations in the Dominican Republic cohort

C. Bass, F. Middleton, C. Muniz, A. Espinoza, M. Santana Jimenez, S. Baser (Pittsburgh, PA, USA)
Plasma biomarker quantification in SCA3 using the Neurology 4-PLEX A kit and the Simoa technology

H. Garcia-Moreno, G. Thomas-Black, A. Heslegrave, H. Zetterberg, P. Giunti (London, United Kingdom)
Plasticity of frequency dependent tremor control in Parkinson disease (PD) subthalamic nucleus (STN) deep brain stimulation (DBS) implanted individuals

E. Hargreaves, D. Schneider, R. DiPaola, J. Chen, S. Danish, D. Caputo (New Brunswick, NJ, USA)
PNPLA6-related Disorder With Expanded Phenotype Including Parkinsonism, Dystonia, And Abnormal Dopamine Transporter Imaging

J. Witt, M. Davis (Seattle, WA, USA)
POLR3A Leukodystrophy presenting with levodopa responsive parkinsonism

K. Kyle, J. Bronstein, Y. Bordelon (Los Angeles, CA, USA)
Poly-ADP-ribose polymerase 1 modulates mitochondrial fission via LRRK2 in a rotenone-induced Parkinson’s disease model

L. Bu, Y. Lu, Y. Liang, Y. Chen, S. Peng (Guangzhou, China)
Poor Sleep Quality is Associated With Fatigue in Early Parkinson’s Disease: A Longitudinal Study in the Early Parkinson’s Disease Longitudinal Singapore Study (PALS) Cohort

M. Koh, C.Y Chua, S. Ng, N. Chia, S.E Saffari, R. Chen, X. Choi, D.L Heng, S. Neo, K.Y Tay, W.L Au, E.K Tan, L. Tan, Z. Xu (Singapore, Singapore)
Population pharmacokinetic analysis of levodopa and carbidopa after subcutaneous administration with and without adjunct oral therapy

T. Birnberg, G. Smania, M. Bjornsson, N. Jonsson, R. Case, S. Oren, L. Adar, M. Karlsson (Rehovot, Israel)
Positional variability in upper limb tremor in both essential and dystonic tremor: A case series

J. Anang (Winnipeg, MB, Canada)
Positive Correlations Between Quality of Life and Sleep Dysfunction in Advanced Parkinson’s Disease Patients Prior to and After 12 Months of Levodopa-Carbidopa Intestinal Gel Treatment: An Analysis From the DUOGLOBE Study

K.R Chaudhuri, J. Boyd, E. Cubo, I. Malaty, F. Pontieri, M. Simu, L. Bergmann, T. Gao, Y. Jalundhwala, P. Kukreja, J. Aldred (London, United Kingdom)
Possible correlations between symptoms suggesting gastroparesis and dyskinesias in advanced Parkinson’s disease

J. Szász, V. Constantin, S. Szatmári, L. Bancu, D. Georgescu, J. Szederjesi, M. Ciorba, A. Racz, I. Mihaly, K. Orbán (Targu Mures, Romania)
Post mortem fatty acid abnormalities in the cerebellar cortex of patients with essential tremor

K. Melançon, L. Berthiaume, C. Tremblay, P. Juline, A. Rajput, A. Rajput, F. Calon (Quebec, QC, Canada)
Postmenopausal hormone therapy and Alzheimer’s disease, dementia, and Parkinson’s disease: A systematic review and time-response meta-analysis

M. wu, M. Ye (Nanjing, China)
Potential Diagnosis Biomarks in Serum Biochemical items of Vascular Parkinsonism Patients

Y. Li, YY. Gao, K. Nie, L.J Wang (Guangzhou, China)
Precise evaluation and exercise prescription for Parkinson’s disease

H. Ziyi (Dalian, China)
Preclinical pharmacology and early clinical development of dopamine D1 positive allosteric modulators (D1PAMs) with therapeutic potential for neuropsychiatric disorders

K. Svensson, H. Meltzer, K. Biglan (Indianapolis, IN, USA)
Predicting dementia in the first 6 years of Parkinson’s disease in the ICICLE-PD cohort

R. Lawson, C. William-Gray, M. Camacho, G. Duncan, T. Khoo, D. Breen, R. Barker, L. Rochester, D. Burn, A. Yarnall (Newcastle upon Tyne, United Kingdom)
Predicting Longitudinal Atrophy in Parkinson’s Disease using SIR model

A. Abdelgawad, S. Rahayel, C. Tremblay, A. Vo, Y.Q Zheng, R. Markello, B. Misic, A. Dagher (Montreal, QC, Canada)
Predicting the effects of Tumor Necrosis Factor inhibition on the risk and age at onset of Parkinson’s disease: A Mendelian randomization study

X. Kang, A. Ploner, N. Pedersen, J. Ludvigsson, S. Bandres-Ciga, A. Noyce, K. Wirdefeldt, D. Williams (Stockholm, Sweden)
Predicting the influence of deep brain stimulation on Parkinson’s disease gait freezing

O. Gavriliuc, S. Paschen, A. Andrusca, C. Schlenstedt, G. Deuschl (Chisinau, Republic of Moldova)
Predictive factors of serious falls in Parkinson’s disease

H. Matsumoto, M. Shiraishi, S. Tochimoto, K. Tanaka, K. Uchino, Y. Hasegawa (Kawasaki, Japan)
Predictors of different progressive trajectories of cognition in Parkinson’s disease

G. Smith, R. Zielinski, C. Venuto, M. Javidnia, K. Kieburtz (Rochester, NY, USA)
Predictors of Falls with Injuries in People with Parkinson’s Disease

H. Meira, I. Rosa, G. Valença, J. Oliveira-Filho, L. Almeida (Salvador, Brazil)
Predictors of quality of life in Machado-Joseph disease: A longitudinal observational study

I. Cunha, P. Silva, J. A Ribeiro, M. Santana, L. P Almeida, C. Januário (Coimbra, Portugal)
Predictors of the progression of dementia with Lewy bodies

A. Chimagomedova, O. Levin (Moscow, Russian Federation)
Predictors of transfer to facility or nursing home after discharge of inpatients with Parkinson’s disease: A Japanese single center retrospective study

Y. Higashi, M. Tabata (Himeji, Japan)
Predictors of Underlying Neurodegeneration in Drug-Induced Parkinsonism

W. Aamodt, J. Dubroff, G. Cheng, B. Taylor, S. Wood, J. Duda, J. Morley (Philadelphia, PA, USA)
Preference and satisfaction of the Deep Brain Stimulation Battery in Patients with Parkinson’s Disease

X. Qiu, CC. Zhang, Z.Y Lin, D.Y Li (Shanghai, China)
Preference and Satisfaction of the Deep Brain Stimulation Battery in the Patients with Hypokinetic Movement Disorders

X. Qiu, CC. Zhang, Z.Y Lin, Y.H Wang, Y.W Wu, D.Y Li (Shanghai, China)
Preferences for exercise in people with Parkinson’s disease: A discrete choice experiment

S. Paul, C. Canning, N. Lofgren, C. Sherrington, D. Lee, J. Bampton, K. Howard (Sydney, Australia)
Prefrontal cortical activity and the control of walking in people with freezing of gait

R. Vitorio, S. Stuart, M. Mancini (Portland, OR, USA)
Pregnancy Outcomes Following Exposure to OnabotulinumtoxinA Update – 29 Years of Safety Observation

M. Brin, A. Adams, L. Parker, A. Ukah, L. Radulian, L. Yedigarova, I. Yushmanova (Irvine, CA, USA)
Premature Cognitive Decline in Young Veterans with mTBI: A Possible Prodromal Signature of Early Stage Parkinson’s Disease

V. Nejtek, M. Salvatore, R. James, H. Alphonso (Fort Worth, TX, USA)
Premotor compensatory mechanisms in Parkinson’s disease with LRRK2-R1441H mutation

S. Sambin, S. Lavisse, C. Decaix, G. Mangone, F. Cormier, B. Le Toullec, S. Lesage, P. Remy, A. Brice, J.C Corvol (Paris, France)
Preoperative higher impulsivity leads to better quality of life after deep brain stimulation in Parkinson’s disease

T. Yamamoto, W. Liu, Y. Yamanaka, M. Asahina, T. Uchiyama, S. Hirano, K. Shimizu, Y. Higuchi, S. Kuwabara (Chiba, Japan)
Prevalence and Characteristics of Postural Deformities in Thai Patients with Parkinson’s Disease

T. Wangthumrong, C. Pongmala, Y. Pitakpatapee, J. Srikajon, M. Vichutavate, P. Srivanitchpoom (Bangkok, Thailand)
Prevalence and Clinical Profile of Common Spinocerebellar Ataxia in Malaysia

L.U Lau, M.D Hajar, Y.S Yakob, M.D Ibrahim (Kuala Lumpur, Malaysia)
Prevalence of apathy in Indian patients with Parkinson’s disease and its correlation with nigrosomal imaging

R. Kandadai, P. Reddy, A. Arora, S. Meka, T. Syed, S. Turaga, R. Borgohain (Hyderabad, India)
Prevalence of Arm Tremor Associated With Dystonia (Arm-TAWD) in patients with Adult-onset Isolated Cervical Dystonia in an Irish population.

I. Ndukwe, S. O'Riordan, M. Hutchinson (Dublin, Ireland)
Prevalence of dysphagia and screening tools in patients with Parkinson’s disease

H. Téllez-Lucero, O. Cárdenaz-Saenz, F. Herrera-Rodríguez, E. Escobar-Valdivia, A. Abundes-Corona, O. Esquivel-Zapata, Y. Ríos-Solís, A. Cervantes-Arriaga, M. Rodríguez-Violante (Mexico City, Mexico)
Prevalence of Neuropsychiatric Symptoms in the Prodromal Stages of Dementia with Lewy Bodies and Parkinson’s Disease Dementia

K. Wyman-Chick, L. Erickson, D. Weintraub, M. Rosenbloom, T. Barclay, M. Barrett (St Paul, MN, USA)
Prevalence of non-motor symptoms in Parkinson’s disease using the Movement Disorder Society-Non-Motor Rating Scale (MDS-NMS) and comparable scales

C. Rodriguez-Blazquez, A. Schrag, D. Weintraub, A. Rizos, K.R Chaudhuri, P. Martinez-Martin (Madrid, Spain)
Prevalence of Spread of Dystonia and its effect on health-related quality of life in an Irish population with adult-onset isolated cervical dystonia.

I. Ndukwe, S. O'Riordan, M. Hutchinson (Dublin, Ireland)
Prevalence, impact, and factors associated with excessive buccal saliva in the COPARK database

S. Perez-Lloret, L. Negre-Pages, P. Damier, A. Delval, P. Derkinderen, A. Destée, M. Fabbri, W. Meissner, A. Rachdi, F. Tison, O. Rascol (Buenos Aires, Argentina)
Prevalence, Impact, and Suboptimal Treatment of Depression in the Fox Insight Cohort

R. Dobkin, M. Gara, S. Mann, K. Rodriguez, A. Interian (Piscataway, NJ, USA)
Pridopidine for the Treatment of Early Huntington’s Disease

M. Geva, R. Reilmann, C. Olanow, M. Leinonen, Y. Cohen, P. Meyer, A. McGarry, O. Sabri, M. Hayden, K. Kieburtz (Herzliya, Israel)
Pridopidine for the treatment of Levodopa-induced Dyskinesia in patients with Parkinson’s disease

M. Geva, A. McGarry, Y. Cohen, T. Johnston, M. de Somer, K. Kieburtz, M. Hayden, J. Brotchie, C. Olanow (Herzliya, Israel)
Primary familial brain calcifications in Sweden

M. Paucar, E. Gilland, H. Almqvist, M. Engvall, I. Björkhem, D. Nilsson, P. Svenningsson (Stockholm, Sweden)
Prion disease with 8 octapeptide repeat insertional mutation presenting with HDL1 phenotype

C. Cooper, D. Hall, B. Fogel, H. Lee, U. Diseases Network (Chicago, IL, USA)
PRO-PARK study: Is there an association between PROfessional occupation and PARKinson´s disease?

E. Natera-Villalba, V. Ros-Castelló, A. Sánchez-Sánchez, A. Gómez-López, P. Pérez-Torre, S. Fanjul-Arbos, G. García-Ribas, C. Estévez-Fraga, I. Parées -Moreno, J.C Martínez-Castrillo, A. Alonso-Cánovas (Madrid, Spain)
Probabilistic response mapping in a cohort of mixed dystonia patients with bilateral pallidal DBS

C. Soares, M. Reich, F. Costa, J. Roothans, R. Vaz, M.J Rosas, J. Volkmann (Porto, Portugal)
Probing the Parieto-Premotor Network in Writer’s Cramp Using Transcranial Magnetic Stimulation

J. Park, P. Mathew, J. Sackett, T. Wu, M. Villegas, M. Hallett (Goyang, Republic of Korea)
Profile of miRNA expression in CSF of Parkinson’s disease identifies miR-409-3p regulating the apoptosis of dopamine neurons

X.L Tan, J.Q Tan, F.Y Ming, LL. Lv, H.N Zhang, B.S Tang, W.Q Yan, RR. Bai, X.K Peng, Q.L Xiao, C.Y Wang (Changsha, China)
Profile of non motor symptoms in familial Parkinson’s disease

A. Patwardhan, P. Pal, R. Yadav, N. Kamble (Bangalore, India)
Profiling Atypical Anxiety in Parkinson’s Disease

E. Forbes, G. Byrne, J. O'Sullivan, J. Yang, N. Dissanayaka (St Lucia, Australia)
Progression in Parkinson’s disease: Variation in motor and non-motor symptoms severity and predictors of decline in cognition, motor function, incapacity and Health Related Quality of Life

P. Bugalho, F. Ladeira, R. Barbosa, J. Marto, C. Borbinha, M. Salavisa, M. Saraiva, L. Conceição, M. Fernandes, B. Meira (Lisboa, Portugal)
Progression of cortical thinning and neuropsychological decline in isolated Rapid Eye Movement sleep behavior disorder

A. Inguanzo, B. Segura, A. Campabadal, A. Abos, C. Uribe, M. Serradell, C. Gaig, J. Santamaria, Y. Compta, C. Junque, A. Iranzo (Barcelona, Spain)
Progression of cortical thinning in Parkinson’s disease

A. Vo, C. Tremblay, S. Rahayel, Y. Yau, A. Dagher (Montréal, QC, Canada)
Progressive supra nuclear palsy phenotype with idiopathic basal ganglia calcification

R. Ramesh, V. Paramanandham, S. Venkatasubramanian, S. Shanmugam (Chennai, India)
Progressive supranuclear palsy: Common metabolic pattern in different variants

G. Martí-Andrés, L. Van Bommel, S. Meles, M. Riverol, R. Valentí, R.V Kogan, R.J Renken, V. Gurvits, T. Van Laar, M. Pagani, E. Prieto, M.R Luquin, K.L Leenders, J. Arbizu (Pamplona, Spain)
Prospective assessment of the lessebo effect in placebo-controlled randomized trials using an expectancy questionnaire

T. Mestre, E. Macklin, C. Coffey, M. Kostrzebski, A. Ascherio, J. Ferreira, M. Schwarzschild, T. Simuni, A. Lang (Ottawa, ON, Canada)
Prospective investigation of the frequency of tardive syndromes in outpatients attending two specialist psychiatry hospitals in Lagos, Nigeria

E. Campbell, B. Fadipe, O. Ojo, S. Oluwaniyi, N. Okubadejo (Surulere, Nigeria)
Protective role of astrocytes on α-synuclein accumulation and propagation

T. Tsunemi, Y. Ishiguro, A. Yoroisaka, K. Krainc, N. Hattori (Tokyo, Japan)
Psychiatric comorbidities in Young Onset Parkinson’s disease

A. Patwardhan, P. Pal, N. Kamble, R. Yadav (Bangalore, India)
Psychometric properties of clinical indicators of device-aided therapy eligibility among Parkinson’s disease patients: Real-world data from 6 countries

K. Chaudhuri, R. Pahwa, S. Isaacson, A. Merola, A. Alobaidi, P. Kandukuri, J.C Parra, L. Bergmann, E. Jones, A. Antonini (London, United Kingdom)
Psychosocial Adjustment to Illness Scale in family carers of patients with Parkinson’s disease: Spanish validation

L. Ambrosio, M.C Portillo, R. Martin-Lanas, M.V Navarta-Sanchez, M. Riverol (Pamplona, Spain)
Pulmonary function in Parkinson’s disease

A. O'Callaghan, W. Gray, S. Bourke, R. Walker (North Shields, United Kingdom)